関連ニュース

Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type

Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript

Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript